BIBLIOGRAPHY:

Published Peer Reviewed Journal Articles

 1.        Andrawis N.S., Kou T.H., Giacomelli F., Wiener J.  Altered calcium regulation in the cardiac plasma membrane in experimental renal hypertension. J. Mol. Cell     Cardiol. 20:625-634,1988

2.        Andrawis N.S., Pratt R.E., Brock T.A., Dzau V.J. Mas oncogene receptor coupling and peptide specificity in Balb 3T3 adn vascular smooth musche cells. Am.J. Med. Sci. 302:329-334,1991.

3.        Andrawis N.S., Dzau V.J., Pratt R.E.  Autocrine stumulation of mas oncogene leads to altered growth control.  Cell Biol. Int. Rep. 16:547-555, 1992.

4.    Andrawis N., Craft N., Abernethy D.R.  Calcium antagonists block angiotensin II- mediated vasoconstrictors in humans. Comparison with their effect on phenylephrine-induced vasoconstriction,  J. Pharmacol.  Exp. Ther. 261:879-884,1992.

5.       Andrawis N.S., Abernethy D.R.  Verapamil Blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle cells.  Biophys.  Biochem. Res.  Comm. 183:767-773, 1992.

6.      Andrawis N.S., Gilligan J., Abernethy D.R. Endothelin-I mediated vasoconstriction: Specific blockade by verapamil.  Clin. Pharm. Ther. 52:583-589, 1992.

7.      Andrawis N.S., Abernethy D.R. Dffect of calcium antagonists on RNA synthesis of NIH 3T3 cells.  Am.J. Med. Sci. 306:137-140, 1993.

8.      Abernethy D.R., Wainer I.W., Longstreth J.A., Andrawis N.S.  Stereoselective Verapamil disposition and dynamics in aging during racemic verapamil   administration. J. Pharmacol. Exp. Ther. 266(2):904-911, 1993.

9.      Andrawis N.S., Ruley E.H., Abernethy D.R. Angiotensin II regulates human vascular smooth muscle a-action gene expression.  Biochem. Biophys. Res. Comm.196:962-969, 1993.

10.    Abernethy D.R., Andrawis N.S. Critical drug interactions: A guide to important examples. Drug Theraphy 23:15-27, 1993.

11.   DePetrillo P.B., Abernethy D.R., Wainer I.W., Andrawis N.S.  Verapamil decreases lymphocyte protein kinase C activity in humans.  Clin. Pharm. Ther. 55:44-49,   1994.

12.    Abernethy D.R., Andrawis N.S. Critical drug interactions: A guide to important examples. Physician Assistant 18:15-21, 1994.

13.    Abernethy D.R., Laurie N., Andrawis N.S. Local angiotensin converting enzyme inhibition blunts endothelin-1 induced increase in forearm vascular resistance. Clin. Pharm. Ther, 58:328-34, 1995.

14.   Andrawis N.S., Wang E., and Abernethy D.R. Endothelin-1 induces increase of total protein synthesis and expression of smooth muscle a-actin gene in vascular smooth muscle cells. Life Science 59(7): 523-528, 1996.

15.   Liu X-K, Darrell R. Abernethy D.R., Li Y., Omar Shahine O. And Andrawis N.S.  Nitric oxide directly inhibits Oct1 DNA binding activity in cultured vascular smooth muscle cells. (submitted)

16.   Shi S-J, Preuss H. G., Abernethy D. R., Li Y., Li X., Jarrell T., and Andrawis N.S. Elevated bood pressure in sugar fed rats is accompanied by levation in angiotensin II and is reversed by vanadium treatment (in press, J. Hypertension).

17.   Donahue S. R., Andrawis N. S., Abernethy D. R. Enzymatically oxidized low density lipoprotein stimuates vascular smooth muscle cell proliferation (Submitted).

18.     Shi S-J, Abernethy DR, Wilcox CS, Welch WJ, Li X, Moussa M, and Andrawis NS. Effects of soudim balance on vascular renin and angiotensinogen mRNA Expression in rats. (Submitted). 

Abstracts

1.      Andrawis N.S., Kuo T.H., Giancomelli F., Wiener J. Calcium antagonist receptors in cardiac sarcolemma of hypertensive rats:  Altered binding characteristics.  Federation Proc. 46:1411, 1987.

2.    Andrawis N.S., Stevension L.F., Pratt R.E., Dzau V.J. Does the mas oncogene encode an angiotensin receptor? Evidence from stably transfected fibroblast and smooth muscle cells. UCLA Symposia; Molecular Biology of the Cardionvascular System, April 10-16, 1989, Keystone, Colorado.

3.    Andrawis N.S., Stevenson L.F., Pratt R.E., Dzau V.J. Autocrine angiotensin stimulation of mas oncogene leads to altered growth control. Hypertension 14:340, 1989.

4.        Andrawis N.S., Dzau V.J., Pratt R.E. Autocrine Stimulation of the mas oncogene modulates the response of 3T3 cells to substance P. 13^th Scientific Meeting of the international Society of Hypertension, Montreal, Canada. P5 25:s101’, 1990.

5.        Andrawis N.S., Dzau V.J., Pratt R.E. Autocrine stimulation of mas oncogene modulates the response or 3T3 cells to substance P. Clinical Research 38(2):242A, 1990.

6.        Andrawis N., Tsai S.-W., Abernethy D.R. alpha-actin expression is suppredded in aging multiple passage cultured rat aortic vascular smooth muscle cells.  Clinical Research 39(2):228A, 1991.

7.        Andrawis N.S., Abernethy D.R. Verapamil blocks basal and angiotensin II-induced synthesis of actin mRNA.  The Pharmacologist 33(3):223, 1991.

8.        Abernethy D.R., Andrawis N.S. Increased angiotensin II responsiveness of vascular smooth muscle cells of aged Fischer 344 rats.  The Pharmacologist 33(3):223, 1991.

9.        Craft N., Andrawis N.S., Abernethy D.R. Comparison of the effets of calcium antagonists on angiotensin II and phenylephrine-induced vasoconstriction.  The Pharmacologist 33(3):204,1991.

10.    Andrawis N.S., Craft N., Abernethy D.R. Differential alpha-adrenergic blockade by calcium antagonists. J. Clin. Pharmalo. 31:841, 1991.

11.    Abernethy D.R., Craft N., Andrawis N. Diltiazem blocks angiotensin II-mediated vasoconstriction in vivo.  Clin Pharmac Therap 49(2):142,1991.

12.    Andrawis N., Craft N., Abernethy D.R. Verapamil blocks angiotensin II-mediated vascular responses.  Clin Pharmac Therap 49(2):201, 1991.

13.    Andrawis N.S., Craft N., Abernethy D.R.  Vascular angiotensin blockade by calcium antagonists.     FASEB J (4):A841, 1991.

14.    Andrawis N.S., Krochmal R., Abernethy D.R. Evidence for a calcium channel-independent induced decrease in cellular hypertrophy by calcium antagonists.  Clin. Pharmacol. Ther. 51:143, 1992.

15.    Andrawis N.S., Abernethy D.R. Growth inhibition of verapamil (VEP) on vascular smooth muscle (VSMC): Blockade of angiotensin II (AII) effect.  Clin. Pharmacol. Ther. 51:143, 1992.

16.    Abernethy Dr., Tsai S.-W., Andrawis N.S.  Acute and chronic responses to Angiotensin II in aging.  Clin. Pharmacol. Ther. 51:176, 1992.

17.    Abernethy D.R., Craft N., Andrawis N.S. Calcium antagonists (CA): a-adrenergic blockade is not a common characteristic.  Clin. Pharmacol. Ther. 51:193,1992.

18.    Tsai S.-W., Andrawis N.S., Abernethy D.R. Verapamil Blocks endothelin-I (ET-I) mediated vascular effects.  The FASEB J. 6:A1004, 1992.

19.    Andrawis N.S., Abernethy D.R. Regualtion of a-actin vascular smooth muscle gene calcium antagonists.  The FASEB J. 6A:1867,1992.

20.    Andrawis N.S., Abernethy D.R. Angiotensin II and verapamil activate positive and negative regulatory elements in the human vascular smooth muscle a-actin gene. Clin. Res. 40:326A, 1992.

21.    Abernethy Dr., Andrawis N.S. Verapamil (VER) blocks fetal calf serum stimulated RNA synthesis in NIH 3T3 fibrobasts.  The FASEB J. 6:A1869, 1992.

22.    Adrawis N., Abernethy D.R.  Calcium antagonists block angiotensin II-mediated vasoconstrictors in humans.  Comparison with their effect on phenylephrine-induced vasoconstriction. J. Pharmacol. Expt. Therap. 261:879-884,1992.

23.    Andrawis N.S., Abernethy D.R. In vivo and in vitro evidence for vascular angiotensin II blockade by calcium antagonists.  American College of Physicians-Rhode Island Chapter Meeting, Providence, RI, April 1992.

24.    DePetrillo P.B., Andrawis N.S., Abernethy D.R.  Verapamil decreases lymphocyte protein kinase C activity in humans.  The Pharmacologist 34:139, 1992.  

25.    Andrawis N.S., Gilligan J., Abernethy D.R. Verapamil selectively blocks Endothelin-I mediated vasoconstriction in humans.  The Pharmacologist 34:148, 1992.

26.    Andrawis N.S., McCoy C.  Isoniazid associated rhabdomyolysis.  American College of Physicians-Rhode Island Chapter, Providence, RI, March 1993.

27.    Andrawis N.S., Gaudet E.E., Heller G. V. Chronic elevation of CK-MB Isoenzymes in a male patient.  American College of Physicians-Rhode Island Chapter, Providence, RI, March 1993.

28.    Craft N., Andrawis N.S., Abernethy D.R. Elevated basal and endothelin-I stimulated a-smooth muscle actin mRNA expression in an aged vascular smooth muscle model. Clin. Res. 41(2):126A, 1993.

29.    Andrawis N.S., T sai S.-W., Abernethy D.R. Angiotensin II and verapamil reguate expression of vascular cytoskeletal proteins. Clin. Pharmacol. Ther. 53(2):205, 1993.

30.    Andrawis N.S., Abernethy D.R. Endothelin-1 regulates total protein synthesis and expression of cytoskeletal proteins. In vascular smooth muscle cell. Clin.  Pharmacol. Ther. 55(2):151.

31.    Abernethy DR., Laurie N., Andrawis N.S. Local angiotensin converting enzyme inhibition blunts endothelin-1 induced increase in forearm vascular resistance.  Clin. Pharmacol. Ther. 55(2):151.

32.    Andrawis N.S., Wang E., Gabra N., Abernethy D.R. Vascular smooth muscle cell cytoskeletal protein regulation by endothelin-1. The FASEB J. 8:A555, 1994.

33.    X-K Liu, D.R. Abernethy, Y. Li, O. Shahine and N.S. Andrawis. Nitric oxide directly inhibits Oct1 DNA binding activity in cultured vascular smooth muscle cells Clin. Pharmacol. Ther, 59:174, 1996.

34.     N.S. Andrawis, J. Hackenburck, Y. Li, and DR. Abernethy. Angiotensin II and endothelin-1 induction of myc and AP-1 transcription factor binding activity in vascular smooth muscle cells is reversed by nitric oxide. Clin. Pharmacol. Ther, 59:176, 1996

35.     D. R. Abernethy, L. Kelly and N.S. Andrawis. Endothelin-1 (ET-1) induces prolonged AP-1 transcription factor DNA binding activity in vascular smooth muscle cells isolated from aged Fischer 344 rats. The FASEB J. 10 (3), A558, 1996

36.    S. R. Donahue, N.S. Andrawis, and D. R. Abernethy. Enzymatically oxidized LDL Increases DNA synthesis and induces AP-1 DNA binding activity. The FASEB J. 10 (3), A271, 1996

37.   Y. Li, D. Rabernethy, and N.S. Andrawis. Nitric oxide directly inhibits vascular smooth muscle AP-1 DNA binding activity. The FASEB J. 10 (3), A444, 1996

38.    X-K Liu, D. R. Abernethy, Y Li, O. Shahine and N. S. Andrawis.  Nitric oxide (NO) directly inhibits Oct1 DNA binding activity in cultured vascular smooth cells (VSMCs). The FASEB J. 10 (3), A271, 1996

39.    X-K Liu, D. R. Abernethy, Y. Li, O. Shahine and N. S. Andrawis. In vitro and in vivo evidence for inhibition of Oct1 DNA binding activity in cultured vascular smooth muscle cells (VSMCs). The FASEB J. 10 (3), A342, 1996

40.   N. S. Andrawis, K. Sandgerg, W. Zheng and , D. R. Abernethy, Vascular smooth muscle cells (VSMCs) from aged Fischer 344 rats have increased angiotensin II (AII)-induced calcium 45 uptake and AII binding. The FASEB J. 10 (3), A769, 1996

41.    Shi S-J, Preuss H. G., Abernethy D. R., Li Y., Li X., Jarrell T., and Adrawis N. S. Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium. Clin. Pharmacol. Ther, 61:207, 1997

42.   Shi S-J, Abernethy DR, Wilcox CS, Welch Wj, Li X, Moussa M, and Andrawis NS. Effects of sodium balance on vascular renin and angiotensinogen mRNA expression in rats. The Pharmacologist March, 1997 

Invited papers, Ph.D. thesis, and book chapters

1.         Andrawis N.S. Doctor of Philosophy Dissertation Research on “Altered calcium regulation in cardiac plasma membrane in experimental renal hypertension” Wayne State University, Detroit, MI, 1988.

2.       Abernethy D.R., Andrawis N.  Hypertension in the elderly. In PRACTICE OF GERIATRICS, 2^nd ed. (E.Calkins, A.B. Ford, and P.R. Katz, Eds.) W.B Saunders Company, Philadelphia, PA, 1992, Chpter 45, pp 454-461.

3.       Andrawis N.S.  Left ventricular function and perfusion in the aging patient with hypertension.  Cardiovascular Update, January 1992.

4.       Abenethy D.R., Andrawis N.S.  Stereoisomeric drugs in therapeutics:  clinical perpectives.  IN DRUG STEREOCHEMISTRY: ANALYTICAL METHODS AND PHARMACOLOGY, 2^nd ed. (Wainer I. W., ed.),, Marcel Dekker, Inc.  New York, 1993, Chapter 15, pp 3859397.

5.       Abernethy D.R., and Andrawis N.S. Pharmacodynamics of calcium antagonist drugs. In PHARMACODYNAMICS AND DRUG DEVELOPMENT: PRESPECTIVES IN CLINICAL PHARMACOLOGY. (N.R. Cutler, J.J. Sramek and P. K. Narang, ed), John Wiley & Sons Ltd, 1994, Capter 14, pp 253-266.